Press Releases

 
Press Releases
  Date Title View
Jul 27, 2015
WALTHAM, Mass., July 27, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) announced today that, in conjunction with the U.S. market introduction of automated testing for galectin-3, clinical and analytical performance data for galectin-3 testing using an Abbott ARCHITECT® automated immunoassay analyzer will be presented at the 2015 Ame...
Jul 15, 2015
WALTHAM, Mass., July 15, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, announced today that it has paid off its secured term loan facility with General Electric Capital Corporation and Comerica Bank. The secured term loan in the aggregate principal amount of $10 million was funded ...
Jul 8, 2015
WALTHAM, Mass., July 8, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, today announced the effectiveness of a one-for-four reverse stock split of its common stock. The reverse stock split took effect at 5:00 pm Eastern Time on July 8, 2015 and the Company's common stock will open for tradin...
Jul 6, 2015
WALTHAM, Mass., July 6, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, today announced that the ARCHITECT® Galectin-3 assay is now available. This automated blood test was cleared by the United States Food and Drug Administration (FDA) for use in conjunction with clinical evaluation as...
May 14, 2015
Net Loss Reduced by 38% and Operating Cash Burn Cut by 42% from First Quarter 2014 Outlook Improved for 2015 WALTHAM, Mass., May 14, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, today reported financial results for the first quarter of 2015. "We continue to prepare...
May 7, 2015
WALTHAM, Mass., May 7, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) today announced that the company will host a conference call and webcast on Thursday, May 14, 2015 at 8:30 a.m. Eastern Time to discuss its Q1 2015 financial results before the market opens. Conference Call Details The conference call may be accessed by ...
Mar 31, 2015
WALTHAM, Mass., March 31, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, today reported that it has filed a 510(k) Premarket Notification with U.S. Food and Drug Administration (FDA) for regulatory clearance of an additional indication for the BGM Galectin-3 Test. The filing incorpo...
Mar 31, 2015
Net Loss Reduced by 49% and Operating Cash Burn Cut by 47% From 2013 First Automated Galectin-3 Testing Expected to Launch in U.S. in Mid-2015 WALTHAM, Mass., March 31, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, today reported financial results for the three months and y...
Mar 26, 2015
WALTHAM, Mass., March 26, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) announced today the publication of a landmark study, in the Journal of the American College of Cardiology, reporting clinical outcome results of the BioImage Study.[1] The BioImage Study, sponsored by BG Medicine in collaboration with pharmaceutical and healthcare co...
Mar 24, 2015
WALTHAM, Mass., March 24, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) today announced that the company will host a conference call and webcast on Tuesday, March 31, 2015 at 8:30 am Eastern Time to discuss its fiscal year 2014 financial results before the market opens. Conference Call Details The conference call may be ...
1
... NextLast
= add release to Briefcase